

## Supporting Information: Part 2 (*in vivo* imaging)

### **Liposomes of $\alpha,\epsilon$ -N,N'-di-stearoyl lysine-derived amide lipid and phospholipid: Incorporation of lipid A-ligand for bacterial targeting and sialic acid as PEGylation alternative for phagocytosis resistance**

Dean Williams,<sup>a</sup> Alissa McAdorey,<sup>b,c</sup> Eric Lei,<sup>a</sup> Greg Harris,<sup>a</sup> Binbing Ling,<sup>a</sup> Debbie Callaghan,<sup>a</sup> Dorothy Fatehi,<sup>a</sup> Angie Verner,<sup>a</sup> Jacqueline Slinn,<sup>a</sup> Maria Moreno,<sup>a</sup> Umar Iqbal,<sup>a</sup> Hui Qian,<sup>d</sup> Hongbin Yan,<sup>b</sup> Wangxue Chen,<sup>a</sup> Wei Zou<sup>a\*</sup>

<sup>a</sup> *Human Health Therapeutic Research Center, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6*

<sup>b</sup> *Department of Chemistry and Centre for Biotechnology, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, Ontario, Canada L2S 3A1*

<sup>c</sup> *Department of Biological Science, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, Ontario, Canada L2S 3A1*

<sup>d</sup> *Nanotechnology Research Center, National Research Council Canada, 11421 Saskatchewan Dr NW, Edmonton, AB T6G 2M9*




## First *in vivo* imaging experiment


- Phospholipids
- Phospholipids/2S-P1000 (1:1)
- Phospholipids/2S-Ps-Sia (1:1)

# *In vivo* Imaging IV (tail vein) inj. of Group 1: Phospholipids M1

Dorsal



Ventral




- High level of signals observed in the liver starting at 5 minutes and persisted at least for 48 hours
- Detectable signal in the bladder starting at 5 minutes.
- Detectable signals observed in the kidney at 15 minutes and peaked at 6 hours.




# *In vivo* Imaging IV (tail vein) inj. of Group 1: Phospholipids M2

Dorsal




Ventral




# *In vivo* Imaging IV (tail vein) inj. of Group 1: Phospholipids M3

Dorsal




Ventral






## Ex vivo Imaging IV (tail vein) inj. of Group 1: Phospholipids




Quantification of ex vivo Imaging IV (tail vein) inj. of Group 1 Phospholipids alone: Total radiant efficiency (avg of 3 mice, mean  $\pm$  SD)




- Highest signals observed in the liver.
- Lower signals observed in spleen and kidneys.

## ***In vivo* Imaging IV (tail vein) inj. of Group 2: Phospholipids /2S-P1000 1:1 M4**

**Dorsal**



**Ventral**




- Drug distributed to whole body within 5 minutes
- High level of signals were observed in the bladder starting at 15 minutes
- Higher signals observed in the liver at 6 and 24 hours then declined at 48 hours
- Body signals persisted at least for 48 hours




## ***In vivo* Imaging IV (tail vein) inj. of Group 2: Phospholipids /2S-P1000 1:1 M5**

**Dorsal**




**Ventral**






# ***In vivo* Imaging IV (tail vein) inj. of Group 2: Phospholipids /2S-P1000 1:1 M6**


**Dorsal**




**Ventral**



## Ex Vivo Imaging IV (tail vein) inj. of Group 2: Phospholipids /2S-P1000 1:1




Quantification of ex vivo Imaging IV (tail vein) inj. of Group 2 Phospholipids/2S-P1000 1:1: Total radiant efficiency (avg of 3 mice, mean  $\pm$  SD)




- Highest signals observed in the liver.
- Lower signals observed in spleen, kidneys and lung.

## ***In vivo* Imaging IV (tail vein) inj. of Group 3: Phospholipids /2S-Sia 1:1 M7**

**Dorsal**



**Ventral**




- NOTE: Large signals in tail vein suggesting failed IV injection.




## ***In vivo* Imaging IV (tail vein) inj. of Group 3: Phospholipids /2S-Sia 1:1 M8**

**Dorsal**



**Ventral**




- Higher level of signals were observed in the kidney and liver starting at 5 minutes.
- High signal in liver persisted for up to 48hrs
- Signals were observed in bladder starting at 5 minutes






# ***In vivo* Imaging IV (tail vein) inj. of Group 3: Phospholipids /2S-Sia 1:1 M9**

**Dorsal**




**Ventral**






## Ex Vivo Imaging IV (tail vein) inj. of Phospholipids /2S-Sia 1:1



Quantification of ex vivo Imaging IV (tail vein) inj. of Group 2 Phospholipids/2S-Sia 1:1: Total radiant efficiency (avg of 3 mice, mean  $\pm$  SD)




- Highest signals observed in the liver.

## Second *in vivo* imaging experiment


- Phospholipids
- Phospholipids/2S-P1000 (3:1)
- Phospholipids/2S-Ps-Sia (3:1)

## *In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids M1

Dorsal



Ventral




- High level of signals observed in the liver and kidney starting at 5 minutes and persisted at least for 48 hours
- Higher signal in the bladder starting at 5 minutes.




# *In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids M2

Dorsal




Ventral




## *In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids M3

Dorsal





Ventral






## Ex vivo Imaging IV (tail vein) inj. (Group of 3): Phospholipids




- n=3, mean  $\pm$  SD
- Highest signals observed in the liver.
- Lower signals observed in spleen and kidneys.

# ***In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P1000 3:1 M1**

**Dorsal**



**Ventral**




- Drug distributed to whole body within 5 minutes
- High level of signals were observed in the mouth and neck area starting at 5 minutes then decline with time
- High signals were observed in the kidney and persisted until 48 hours.
- Higher signals observed in the liver at 6 and 24 hours then declined at 48 hours
- Body signals persisted at least for 48 hours




# *In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P1000 3:1 M2

Dorsal




Ventral






# *In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P1000 3:1 M3



Dorsal



Ventral



## Ex Vivo Imaging IV (tail vein) inj. of Phospholipids/2S-P1000 3:1 (Drug 3B)




- Highest signals observed in the liver.
- Lower signals in lung, kidney and spleen.




## ***In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P3-Sia 3:1 M1**

**Dorsal**



**Ventral**




- Drug distributed to centre of the body within 5 minutes
- High level of signals were observed in the mouth and neck area starting at 5 minutes then decline with time
- High signals were observed in the kidney and persisted until 48 hours.
- Higher signals observed in the liver at 6 and 24 hours and persisted until 48 hours
- Body signals persisted at least for 48 hours




## ***In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P3-Sia 3:1 M2**

**Dorsal**



**Ventral**




- Higher level of signals were observed in the kidney and liver starting at 5 minutes.
- High signal in liver persisted for up to 48hrs
- Signals were observed in bladder starting at 5 minutes




## ***In vivo* Imaging IV (tail vein) inj. (Group of 3): Phospholipids/2S-P3-Sia 3:1 M3**

**Dorsal**





**Ventral**





## Ex Vivo Imaging IV (tail vein) inj. of Phospholipids/2S-P3-Sia 3:1



- Highest signals observed in the liver.
- Lower signals in lung, kidney and spleen.